New Study Adds Vytorin Woes For Merck, Schering

Law360, New York (July 22, 2008, 12:00 AM EDT) -- Merck & Co. and Schering-Plough Corp. are facing an increasingly uphill battle to ward off concerns over their jointly marketed cholesterol treatment Vytorin, with a new study reportedly showing that the blockbuster drug is no more effective than a placebo in treating patients with serious heart conditions.

The results of the study, announced Monday by a team of European researchers, found that Vytorin did not prevent complications from aortic stenosis, a condition in which blood flow to the heart is blocked, leading to congestive heart failure...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.